Cognitive Impact of Pomegranate Polyphenols Following Ischemic Stroke
NCT ID: NCT02442804
Last Updated: 2017-08-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
16 participants
INTERVENTIONAL
2015-06-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.
NCT02526225
Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
NCT06861426
Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke
NCT06140888
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
NCT07220538
Efficacy and Safety of Sodium Oligomannate in the Prevention of PSCI
NCT05545605
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stroke - POMx
Pomegranate supplement (1g) by mouth twice per day for 7 days
POMx
Pomegranate supplement (1g) by mouth twice per day for 7 days
Stroke - Placebo
Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
Placebo
Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
POMx
Pomegranate supplement (1g) by mouth twice per day for 7 days
Placebo
Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fluent in English
* Between the age of 18 and 89 years old
Exclusion Criteria
* Global aphasia
* Pregnant
* History of allergy to pomegranates
* History of traumatic brain injury
* Neurodegenerative disease or neurologic condition with known cognitive impact (e.g., Alzheimer's disease)
* Active renal disease
* Active liver disease
* Intracerebral hemorrhage in past 6 months
* Neurosurgery in past month
* Taking warfarin (Coumadin)
18 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Loma Linda University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Bellone
MA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Loma Linda University East Campus Hospital
Loma Linda, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5150112
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.